Determination of the Degree of Esterification in Heparin Benzylates During Synthesis of Enoxaparin, a Domestic Analog of Low-Molecular-Mass Heparin


Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription Access

Abstract

The esterification stage of low-molecular-mass heparin (enoxaparin) production by hydrolytic depolymerization of unfractionated heparin was studied and consisted of treating previously synthesized benzethonium heparinate with benzyl chloride. The content of benzyl moieties in the synthesized heparin benzylates and their degree of benzylation were determined using HPLC, PMR, and 13C NMR methods. A carboxylic-acid content of 0.13 ± 0.01 mol/g in the starting heparin was calculated from these results. A new method for estimating the degree of heparin benzylation from PMR and HPLC data was proposed. The benzyl content in the heparin benzylates increased with increasing molar excess of benzyl chloride.

About the authors

L. E. Frumin

M. V. Lomonosov Institute of Fine Chemical Technologies, Russian Technological University

Email: kristina.yureva1994@mail.ru
Russian Federation, 78 Prosp. Vernadskogo, Moscow, 119454

K. P. Yur’eva

M. V. Lomonosov Institute of Fine Chemical Technologies, Russian Technological University

Author for correspondence.
Email: kristina.yureva1994@mail.ru
Russian Federation, 78 Prosp. Vernadskogo, Moscow, 119454

A. V. Matveev

M. V. Lomonosov Institute of Fine Chemical Technologies, Russian Technological University

Email: kristina.yureva1994@mail.ru
Russian Federation, 78 Prosp. Vernadskogo, Moscow, 119454

E. V. Vorfolomeeva

M. V. Lomonosov Institute of Fine Chemical Technologies, Russian Technological University; Institute of Pharmaceutical Technologies

Email: kristina.yureva1994@mail.ru
Russian Federation, 78 Prosp. Vernadskogo, Moscow, 119454; Skolkovo, Moscow, 121353

I. A. Vostrov

Institute of Pharmaceutical Technologies

Email: kristina.yureva1994@mail.ru
Russian Federation, Skolkovo, Moscow, 121353

G. V. Zatonskii

G. F. Gause Institute of New Antibiotics

Email: kristina.yureva1994@mail.ru
Russian Federation, 11 Bol’shaya Pirogovskaya St., Moscow, 119435

D. I. Prokhorov

M. V. Lomonosov Institute of Fine Chemical Technologies, Russian Technological University

Email: kristina.yureva1994@mail.ru
Russian Federation, 78 Prosp. Vernadskogo, Moscow, 119454

E. S. Zhavoronok

M. V. Lomonosov Institute of Fine Chemical Technologies, Russian Technological University; Institute of Pharmaceutical Technologies

Email: kristina.yureva1994@mail.ru
Russian Federation, 78 Prosp. Vernadskogo, Moscow, 119454; Skolkovo, Moscow, 121353

A. V. Panov

M. V. Lomonosov Institute of Fine Chemical Technologies, Russian Technological University; Institute of Pharmaceutical Technologies

Email: kristina.yureva1994@mail.ru
Russian Federation, 78 Prosp. Vernadskogo, Moscow, 119454; Skolkovo, Moscow, 121353

L. E. Grebenkina

M. V. Lomonosov Institute of Fine Chemical Technologies, Russian Technological University

Email: kristina.yureva1994@mail.ru
Russian Federation, 78 Prosp. Vernadskogo, Moscow, 119454

N. V. Pyatigorskaya

I. M. Sechenov First Moscow State Medical University (Sechenov University), Ministry of Health of Russia

Email: kristina.yureva1994@mail.ru
Russian Federation, Moscow

G. É. Brkich

I. M. Sechenov First Moscow State Medical University (Sechenov University), Ministry of Health of Russia

Email: kristina.yureva1994@mail.ru
Russian Federation, Moscow

S. A. Kedik

M. V. Lomonosov Institute of Fine Chemical Technologies, Russian Technological University; Institute of Pharmaceutical Technologies

Email: kristina.yureva1994@mail.ru
Russian Federation, 78 Prosp. Vernadskogo, Moscow, 119454; Skolkovo, Moscow, 121353


Copyright (c) 2019 Springer Science+Business Media, LLC, part of Springer Nature

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies